Great Lakes Advisors LLC decreased its stake in shares of Luminex Corp. (NASDAQ:LMNX) by 24.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 300,894 shares of the company’s stock after selling 96,670 shares during the period. Great Lakes Advisors LLC owned about 0.69% of Luminex Corp. worth $6,836,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of LMNX. Vanguard Group Inc. increased its stake in Luminex Corp. by 2.9% in the second quarter. Vanguard Group Inc. now owns 3,059,081 shares of the company’s stock valued at $61,885,000 after buying an additional 86,935 shares in the last quarter. Acadian Asset Management LLC increased its stake in Luminex Corp. by 16.5% in the second quarter. Acadian Asset Management LLC now owns 1,622,291 shares of the company’s stock valued at $32,819,000 after buying an additional 229,781 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Luminex Corp. by 15.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,437,400 shares of the company’s stock valued at $29,078,000 after buying an additional 197,506 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Luminex Corp. by 3.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,126,015 shares of the company’s stock valued at $22,779,000 after buying an additional 42,501 shares in the last quarter. Finally, Kalmar Investments Inc. DE increased its stake in Luminex Corp. by 0.5% in the third quarter. Kalmar Investments Inc. DE now owns 951,585 shares of the company’s stock valued at $21,620,000 after buying an additional 4,610 shares in the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Luminex Corp. (NASDAQ:LMNX)

Luminex Corp. (NASDAQ:LMNX) traded down 1.88% during trading on Wednesday, reaching $20.35. 72,494 shares of the company’s stock traded hands. Luminex Corp. has a 12-month low of $17.29 and a 12-month high of $23.75. The company has a 50 day moving average price of $20.93 and a 200-day moving average price of $21.17. The company has a market cap of $886.93 million, a PE ratio of 23.47 and a beta of 0.57.

Luminex Corp. (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, October 31st. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.09. Luminex Corp. had a net margin of 14.51% and a return on equity of 11.95%. The business earned $71.20 million during the quarter, compared to analysts’ expectations of $68.90 million. During the same quarter in the prior year, the company posted $0.22 EPS. The business’s revenue for the quarter was up 17.5% on a year-over-year basis. On average, equities research analysts forecast that Luminex Corp. will post $0.52 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Luminex Corp. (LMNX) Shares Sold by Great Lakes Advisors LLC” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/30/luminex-corp-lmnx-shares-sold-by-great-lakes-advisors-llc.html.

Several analysts have recently weighed in on LMNX shares. JPMorgan Chase & Co. raised shares of Luminex Corp. from an “underweight” rating to a “neutral” rating and lifted their price target for the company from $18.00 to $22.00 in a research note on Thursday, August 18th. Zacks Investment Research downgraded shares of Luminex Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday. William Blair reissued a “market perform” rating on shares of Luminex Corp. in a research note on Tuesday, November 1st. Finally, Avondale Partners initiated coverage on shares of Luminex Corp. in a research note on Wednesday, October 12th. They issued an “outperform” rating and a $27.00 price objective for the company. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Luminex Corp. has a consensus rating of “Hold” and an average price target of $23.00.

In related news, CEO Nachum Shamir acquired 6,000 shares of the stock in a transaction that occurred on Thursday, November 3rd. The stock was purchased at an average price of $18.22 per share, with a total value of $109,320.00. Following the transaction, the chief executive officer now owns 105,010 shares of the company’s stock, valued at approximately $1,913,282.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Harriss T. Currie acquired 4,100 shares of the stock in a transaction that occurred on Thursday, November 3rd. The shares were bought at an average cost of $18.20 per share, with a total value of $74,620.00. The disclosure for this purchase can be found here. 6.90% of the stock is currently owned by insiders.

About Luminex Corp.

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.

5 Day Chart for NASDAQ:LMNX

Receive News & Stock Ratings for Luminex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corp. and related stocks with our FREE daily email newsletter.